Celgene Thalomid Multiple Myeloma sNDA Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene said that it will submit a completed study which compares thalidomide plus dexamethasone to dexamethasone alone in previously untreated patients, as well as additional data. Accelerated approval is possible in six to nine months, the company says.
You may also be interested in...
Celgene’s Thalomid “Approvable” Again For Multiple Myeloma
FDA’s second approvable letter calls for labeling changes specific to an indication for newly diagnosed multiple myeloma.
Celgene’s Thalomid “Approvable” Again For Multiple Myeloma
FDA’s second approvable letter calls for labeling changes specific to an indication for newly diagnosed multiple myeloma.
FDA Cites Celgene For Tardy Adverse Event Reporting On Thalomid
Celgene has hired a new contractor to process adverse event reports for thalidomide, although the agency says it will have to “assess the adequacy of the correction during a future inspection.” An FDA letter cites 82 instances of delayed reports.